ClinicalTrials.gg
TerminatedNCT01514149Updated Jul 19, 2017Results posted

Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy

A Phase 2 interventional study of CJC-1134-PC Injection and Weekly placebo for CJC-1134-PC Injection in Type 2 Diabetes Mellitus (T2DM), sponsored by ConjuChem. Terminated at 22 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-07-19.

Sponsored by ConjuChem · Phase 2, Interventional, and Treatment

Why this study was terminated
Business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States — 343 open to participants now, 478 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Enrollment
1,609th of 2,957
73 · median 90
Started
2011
with 151 others
Phase 2
391 of 3,304
24 open now
Registered
1,176th of 3,304
by date

Among the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 1,609th largest by enrollment of the 2,957 interventional ones that give a count, is one of 152 that started in 2011, is one of 391 in phase 2, and was the 1,176th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

343 of the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

338 more — sign in →

All 343 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

DM200-103 is a dose-ranging study to evaluate the efficacy and safety of 17 weeks of weekly injections of CJC-1134-PC in patients with Type 2 Diabetes Mellitus on metformin monotherapy.

Read the detailed description

DM200-103 is a dose-ranging study to evaluate the efficacy and safety of 17 weeks of weekly injections of CJC-1134-PC in patients with Type 2 Diabetes Mellitus (T2DM) on metformin monotherapy. This study will be a randomized, double-blind comparison of CJC-1134-PC versus placebo. Patients taking metformin will continue to take their metformin at the same dose for the duration of the study.

Patients with T2DM, who meet all the inclusion criteria and none of the exclusion criteria, will be randomly assigned to a treatment arm. All patients will undergo weekly clinic visits to receive 17 weeks of study treatment, including the titration period.

CJC-1134-PC or placebo treatment will be administered weekly by subcutaneous injection in the abdomen to patients in a fasting state. Patients will be closely monitored and evaluated for toxicity on an ongoing basis.

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)

Keywords

  • Type 2 Diabetes Mellitus
  • T2DM
  • diabetes
  • ConjuChem
  • GLP-1
  • Glucagon-like peptide-1
  • exendin-4
  • modified exendin-4
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women 18 to 70 years of age, inclusive
  • of 27 to 45 kg/m2
  • Diagnosed with T2DM for at least 6 months before screening
  • Stable daily dose of metformin monotherapy of ≥1000 mg for at least 3 months before screening
  • FPG ≤240 mg/dL at screening
  • ≥7.0% and ≤11% at screening
  • A 12-lead recording without arrhythmia, left bundle-branch block, or interval

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women
  • Use of a weight control treatment, including over-the-counter medications (includes herbal supplements), or a significant change in body weight (at least ±10%) in the 3 months before screening
  • Treatment with any oral antidiabetic agent other than metformin within the 3 months before screening
  • Treatment with insulin for longer than 1 week within the 3 months before screening or any treatment with insulin within the 2 weeks before screening
  • Previous treatment with a glucagon-like peptide 1 (GLP-1) analog or other incretin therapy
  • Receipt of any experimental drug in a clinical trial within 30 days before administration of study drug or receipt of any antidiabetic product within 3 months before screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Arm 1 - Weekly CJC-1134-PC

    Drug: CJC-1134-PC Injection

  • Experimental
    Arm 2 - Weekly CJC-1134-PC

    Drug: CJC-1134-PC Injection

  • Experimental
    Arm 3 - Weekly CJC-1134-PC

    Drug: CJC-1134-PC Injection

  • Experimental
    Arm 4 - Weekly CJC-1134-PC

    Drug: CJC-1134-PC Injection

  • Placebo comparator
    Arm 5 - Weekly Placebo

    Drug: Weekly placebo for CJC-1134-PC Injection

Interventions

  • CJC-1134-PC administered weekly by subcutaneous injection

    Also known as: metformin

  • DrugWeekly placebo for CJC-1134-PC Injection

    Weekly placebo for CJC-1134-PC administered weekly by subcutaneous injection

    Also known as: metformin

06

What researchers measure

Primary outcomes

  1. Glycosylated Hemoglobin Change From Baseline (CFB) to Week 18

    Time frame: CFB to Week 18

Secondary outcomes

  1. Fasting Body Weight CFB to Week 18

    Time frame: CFB to Week 18

  2. Time to Hyperglycemia Rescue

    Time frame: 18 weeks

07

Results

Posted Jul 19, 2017

Participant flow

Participant flow — Overall Study
MilestoneArm 1 - Weekly CJC-1134-PCArm 2 - Weekly CJC-1134-PCArm 3 - Weekly CJC-1134-PCArm 4 - Weekly CJC-1134-PCArm 5 - Weekly Placebo
Started1515141415
Completed1214111314
Not completed31311

Outcome measures

PrimaryGlycosylated Hemoglobin Change From Baseline (CFB) to Week 18
Time frame:
CFB to Week 18
Reported as:
Mean · Percent (%)
Glycosylated Hemoglobin Change From Baseline (CFB) to Week 18
Percent (%)Arm 1 - Weekly CJC-1134-PCArm 2 - Weekly CJC-1134-PCArm 3 - Weekly CJC-1134-PCArm 4 - Weekly CJC-1134-PCArm 5 - Weekly Placebo
Glycosylated Hemoglobin Change From Baseline (CFB) to Week 18-0.56 ± 0.597-0.56 ± 0.627-0.95 ± 0.746-0.95 ± 0.828-0.13 ± 0.811
SecondaryFasting Body Weight CFB to Week 18
Time frame:
CFB to Week 18
Reported as:
Mean · kg
Fasting Body Weight CFB to Week 18
kgArm 1 - Weekly CJC-1134-PCArm 2 - Weekly CJC-1134-PCArm 3 - Weekly CJC-1134-PCArm 4 - Weekly CJC-1134-PCArm 5 - Weekly Placebo
Fasting Body Weight CFB to Week 18-1.91 ± 1.624-0.14 ± 4.122-1.37 ± 2.182-0.92 ± 1.999-1.85 ± 4.083
SecondaryTime to Hyperglycemia Rescue
Time frame:
18 weeks
Reported as:
Mean · days
Time to Hyperglycemia Rescue
daysArm 1 - Weekly CJC-1134-PCArm 2 - Weekly CJC-1134-PCArm 3 - Weekly CJC-1134-PCArm 4 - Weekly CJC-1134-PCArm 5 - Weekly Placebo
Time to Hyperglycemia RescueNA ± NA47.0 ± 53.74NA ± NANA ± NA57.0 ± NA

Adverse events

Collected over 18 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1 - Weekly CJC-1134-PC0/12 (0%)0/12 (0%)3/12 (25%)
Arm 2 - Weekly CJC-1134-PC0/15 (0%)0/15 (0%)11/15 (73.3%)
Arm 3 - Weekly CJC-1134-PC0/13 (0%)0/13 (0%)8/13 (61.5%)
Arm 4 - Weekly CJC-1134-PC0/13 (0%)0/13 (0%)8/13 (61.5%)
Arm 5 - Weekly Placebo0/14 (0%)0/14 (0%)5/14 (35.7%)
Most frequent other events
Most frequent other events
EventArm 1 - Weekly CJC-1134-PCArm 2 - Weekly CJC-1134-PCArm 3 - Weekly CJC-1134-PCArm 4 - Weekly CJC-1134-PCArm 5 - Weekly Placebo
NauseaGastrointestinal disorders1/127/155/136/131/14
VomitingGastrointestinal disorders1/122/151/135/130/14
DiarrhoeaGastrointestinal disorders0/120/151/133/132/14
HeadacheNervous system disorders0/122/150/131/131/14
Upper respiratory tract infectionInfections and infestations0/122/150/130/131/14
Influenza like illnessGeneral disorders1/121/150/131/130/14
ArthralgiaMusculoskeletal and connective tissue disorders0/121/151/131/131/14
HypoglycemiaMetabolism and nutrition disorders0/121/151/131/130/14

Baseline characteristics

Intent to Treat population

Age, Customized
Age, Customized(Participants)Arm 1 - Weekly CJC-1134-PCArm 2 - Weekly CJC-1134-PCArm 3 - Weekly CJC-1134-PCArm 4 - Weekly CJC-1134-PCArm 5 - Weekly PlaceboTotal
18 to 70 years151514141573
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1 - Weekly CJC-1134-PCArm 2 - Weekly CJC-1134-PCArm 3 - Weekly CJC-1134-PCArm 4 - Weekly CJC-1134-PCArm 5 - Weekly PlaceboTotal
Female6768431
Male98861142
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Arm 1 - Weekly CJC-1134-PCArm 2 - Weekly CJC-1134-PCArm 3 - Weekly CJC-1134-PCArm 4 - Weekly CJC-1134-PCArm 5 - Weekly PlaceboTotal
Count of participants—————0
08

Study locations

22 sites
  • Research Site
    Phoenix, Arizona 85018, United States
  • Research Site
    Inglewood, California 90301, United States
  • Research Site
    Tarzana, California 91356, United States
  • Research Site
    Ventura, California 93003, United States
  • Research Site
    Wellington, Florida 33414, United States
  • Research Site
    Idaho Falls, Idaho 83404, United States
  • Research Site
    Lexington, Kentucky 40504, United States
  • Research Site
    Brighton, Massachusetts 02135, United States
  • Research Site
    Greensboro, North Carolina 27405, United States
  • Research Site
    Eugene, Oregon 97401, United States
  • Research Site
    Altoona, Pennsylvania 16602, United States
  • Research Site
    East Providence, Rhode Island 02915, United States
  • Research Site
    Charleston, South Carolina 29407, United States
  • Research Site
    Taylors, South Carolina 29687, United States
  • Research Site
    Austin, Texas 78758, United States
  • Research Site
    Dallas, Texas 75231, United States
  • Research Site
    San Antonio, Texas 78249, United States
  • Research Site
    Salt Lake City, Utah 84107, United States
  • Research Site
    Henrico, Virginia 23233, United States
  • Research Site
    Vancouver, British Columbia, Canada
  • Research Site
    Smiths Falls, Ontario, Canada
  • Research Site
    Toronto, Ontario, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of May 2012 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2017, 5 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2011
First posted
Jan 20, 2012
Start
Sep 2011
Primary completionActual
May 2012
CompletionActual
Mar 2013
Results first posted
Jul 19, 2017
Last update
Jul 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01514149
Lead sponsor
ConjuChem
Responsible party
Sponsor
First posted
Jan 20, 2012
Start date
Sep 2011
Primary completion
May 2012
Completion
Mar 2013
Results posted
Jul 19, 2017
Last update
Jul 19, 2017

Study contacts

Patrick Soon-Shiong, MD
study director · Chief Executive Officer
Robert Henry, MD
principal investigator

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albenatide

Start the discussion